6/9/2021 7:17:55 AM
Karyopharm To Present XPOVIO Data At EHA 2021 Virtual Congress
6/8/2021 8:33:16 PM
Karyopharm Therapeutics Announces Updated Data Of Eltanexor In Patients With Hypomethylating Agent Refractory MDS
6/3/2021 7:06:27 AM
Karyopharm Announces XPOVIO Is Now Available In Additional Strength Tablets
6/2/2021 7:25:45 AM
Karyopharm Gets Conditional Marketing Authorization In UK For NEXPOVIO In Combination With Dexamethasone
5/4/2021 8:27:35 AM
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
5/3/2021 7:14:31 AM
Karyopharm Q1 Net Loss Per Share $0.77 Vs Net Loss Per Share $0.78 Last Year
5/3/2021 7:02:19 AM
Karyopharm Therapeutics Appoints Richard Paulson As President And CEO, Effective May 3, 2021
4/26/2021 7:23:39 AM
Karyopharm: EMA Validates Type II Variation MAA For NEXPOVIO With Velcade And Dexamethasone
4/19/2021 7:26:33 AM
Karyopharm Announces Publication Of Health-Related Quality Of Life Outcomes From Phase 3 SEAL Study Of Selinexor
2/11/2021 7:59:59 AM
Karyopharm Q4 Net Loss $43.4 Mln Or $0.59/shr Vs Net Loss $48.6 Mln Or $0.76/shr Prior Year
2/4/2021 7:54:15 AM
Karyopharm's XPOVIO Gets Regulatory Approval In Israel For Treatment Of Patients With Multiple Myeloma And DLBCL
1/29/2021 8:40:10 AM
Karyopharm Gets Positive CHMP Opinion For NEXPOVIO For Treatment Of Patients With Refractory Multiple Myeloma
1/11/2021 8:30:32 AM
Karyopharm Expects Q4 Total Revenues To Be $35.0 Mln - $36.0 Mln
12/20/2020 7:49:31 PM
Karyopharm Therapeutics Gets FDA Approval Of XPOVIO As Treatment For Patients With Multiple Myeloma
12/15/2020 7:14:36 AM
Karyopharm Therapeutics Appoints Michael Mano As SVP, General Counsel